肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
2期
135-138
,共4页
温本%杨志华%颜劲%郑文滔
溫本%楊誌華%顏勁%鄭文滔
온본%양지화%안경%정문도
鼻咽癌%多西紫杉醇%放疗增敏
鼻嚥癌%多西紫杉醇%放療增敏
비인암%다서자삼순%방료증민
Nasopharyngeal carcinoma%Docetaxel%Radiosensitizer
目的:研究多西紫杉醇在鼻咽癌放疗过程中的增敏作用及不良反应。方法将60例经病理确诊为鼻咽癌的患者随机分成实验组和对照组,每组30例。对照组行单纯放疗,实验组在放疗同时给予静滴多西紫杉醇40 mg,1次/周,治疗1个月后比较两组的治疗效果及不良反应。结果治疗后,实验组的总有效率为83.33%,对照组的总有效率为53.33%,差异有统计学意义(P<0.05);两组间不良反应如白细胞下降、口干咽痛、皮肤反应、恶心、纳差的发生率比较,差异无统计学意义(P>0.05)。结论多西紫杉醇联合放疗治疗鼻咽癌,疗效明显优于单纯放疗,且不增加不良反应,值得在临床推广应用和进一步研究。
目的:研究多西紫杉醇在鼻嚥癌放療過程中的增敏作用及不良反應。方法將60例經病理確診為鼻嚥癌的患者隨機分成實驗組和對照組,每組30例。對照組行單純放療,實驗組在放療同時給予靜滴多西紫杉醇40 mg,1次/週,治療1箇月後比較兩組的治療效果及不良反應。結果治療後,實驗組的總有效率為83.33%,對照組的總有效率為53.33%,差異有統計學意義(P<0.05);兩組間不良反應如白細胞下降、口榦嚥痛、皮膚反應、噁心、納差的髮生率比較,差異無統計學意義(P>0.05)。結論多西紫杉醇聯閤放療治療鼻嚥癌,療效明顯優于單純放療,且不增加不良反應,值得在臨床推廣應用和進一步研究。
목적:연구다서자삼순재비인암방료과정중적증민작용급불량반응。방법장60례경병리학진위비인암적환자수궤분성실험조화대조조,매조30례。대조조행단순방료,실험조재방료동시급여정적다서자삼순40 mg,1차/주,치료1개월후비교량조적치료효과급불량반응。결과치료후,실험조적총유효솔위83.33%,대조조적총유효솔위53.33%,차이유통계학의의(P<0.05);량조간불량반응여백세포하강、구간인통、피부반응、악심、납차적발생솔비교,차이무통계학의의(P>0.05)。결론다서자삼순연합방료치료비인암,료효명현우우단순방료,차불증가불량반응,치득재림상추엄응용화진일보연구。
Objective To study the sensitization effect and safety of Docetaxel on the radiotherapy of nasopharyngeal carci-noma. Methods Sixty cases of nasopharyngeal carcinoma patients confirmed by pathological diagnosis were randomly divided into the experimental group and control group, 30 cases in each group. The control group adopted single radiotherapy, while the experimental group was added with static drops of docetaxel 40 mg, 1 time per week. The therapeutic effect and adverse reac-tions were observed and compared between two groups after 1-month treatment. Results The total effective rate of experimental group and control group were respectively 83.33%and 53.33%, with statistically significant difference (P<0.05).There were no significant differences in the incidence rate of adverse reactions such as leukopenia, pharyngalgia, cutaneous reaction, nausea and vomitting between two groups (P>0.05). Conclusion Docetaxel combined with radiotherapy was more effective than single radiotherapy in the treatment of nasopharyngeal carcinoma, and would not increase the adverse reactions. It was worthy of clini-cal application as well as further study.